IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway

References

• Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–1287.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Ryan CE, Davids MS. BCL-2 inhibitors, present and future. Cancer J. 2019;25(6):401–409.
   PubMed Web of Science ®Google Scholar
• Kapoor I, Bodo J, Hill BT, et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11(11):941.
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1–17.
   PubMed Web of Science ®Google Scholar
• Kittai AS, Woyach JA. Resistance mechanisms to targeted agents in chronic lymphocytic leukemia. Cancer J. 2019;25(6):428–435.
   PubMed Web of Science ®Google Scholar
• Rozovski U, Wu JY, Harris DM, et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014;123(24):3797–3802.
   PubMed Web of Science ®Google Scholar
• Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016;1863(3):401–413.
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase cdelta. Blood. 2002;100(10):3741–3748.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peubez C, Jayne S, et al. Differential activation of pro-survival pathways in response to CD40LG/IL4 stimulation in chronic lymphocytic leukaemia cells. Br J Haematol. 2019;184(5):867–869.
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–1621.
   PubMed Web of Science ®Google Scholar
• Bürgler S, Gimeno A, Parente-Ribes A, et al. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism. J Immunol. 2015;194(2):827–835.
   PubMed Web of Science ®Google Scholar
• Burgler S. Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target. Crit Rev Immunol. 2015;35(5):417–432.
   PubMed Web of Science ®Google Scholar
• Bauvois B, Pramil E, Jondreville L, et al. Activation of interferon signaling in chronic lymphocytic leukemia cells contributes to apoptosis resistance via a JAK-Src/STAT3/mcl-1 signaling pathway. Biomedicines. 2021;9(2):188.
   PubMed Web of Science ®Google Scholar
• Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 2011;117(9):2668–2680.
   PubMed Web of Science ®Google Scholar
• Hazan-Halevy I, Harris D, Liu Z, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010;115(14):2852–2863.
   PubMed Web of Science ®Google Scholar
• Boudny M, Trbusek M. The important role of STAT3 in chronic lymphocytic leukaemia biology. Klin Onkol. 2020;33(1):32–38.
   PubMedGoogle Scholar
• Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3705–3715.
   PubMed Web of Science ®Google Scholar
• Bojarczuk K, Sasi BK, Gobessi S, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127(25):3192–3201.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302-6–e306.
   PubMed Web of Science ®Google Scholar
• Chen Y, Germano S, Clements C, et al. Pro-survival signal inhibition by CDK inhibitor dinaciclib in chronic lymphocytic leukaemia. Br J Haematol. 2016;175(4):641–651.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Song T, Chai G, Liu Y, et al. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br J Pharmacol. 2016;173(3):471–483.
   PubMed Web of Science ®Google Scholar
• Mazumder S, Choudhary GS, Al-Harbi S, et al. Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72(12):3069–3079.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–1597.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res. 2021;165:105463.
   PubMed Web of Science ®Google Scholar
• Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib. Recent Results Cancer Res. 2018;212:119–132.
   PubMedGoogle Scholar
• Jain P, Keating M, Renner S, et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017;4(2):e67–e74.
   PubMed Web of Science ®Google Scholar
• Spaner DE, McCaw L, Wang G, et al. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial. Cancer Med. 2019;8(4):1540–1550.
   PubMed Web of Science ®Google Scholar